The scientists involved in the treatment of Baby KJ have reported that the FDA's rigorous standards present substantial challenges in expanding bespoke gene editing applications.
These regulatory requirements could hinder the ability to replicate the success achieved with Baby KJ for other patients needing similar interventions.
As the field of gene editing evolves, understanding the implications of these regulations will be critical for future infrastructure and capacity planning in therapeutic development.